$50.36
2.36% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$49.20
+0.01 0.02% 1M
-4.23 7.92% 6M
+2.16 4.59% YTD
-30.96 38.62% 1Y
+15.50 45.99% 3Y
+35.64 262.83% 5Y
+42.71 658.09% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.74 1.52%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $5.81b
Enterprise Value $5.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,734.11
P/S ratio (TTM) P/S ratio 1,803.20
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -58.81%
Revenue (TTM) Revenue $3.22m
EBIT (operating result TTM) EBIT $-524.63m
Free Cash Flow (TTM) Free Cash Flow $-407.05m
Cash position $1.01b
EPS (TTM) EPS $-5.39
P/E forward negative
P/S forward 1,770.36
EV/Sales forward 1,702.54
Short interest 18.14%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Cytokinetics, Incorporated forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
79%
Hold
21%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.22 3.22
59% 59%
100%
- Direct Costs 13 13
33% 33%
419%
-10 -10
337% 337%
-319%
- Selling and Administrative Expenses 184 184
6% 6%
5,702%
- Research and Development Expense 317 317
2% 2%
9,853%
-511 -511
5% 5%
-15,874%
- Depreciation and Amortization 13 13
33% 33%
419%
EBIT (Operating Income) EBIT -525 -525
6% 6%
-16,293%
Net Profit -576 -576
9% 9%
-17,901%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
GlobeNewsWire
about 19 hours ago
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 6,066 performance stock units (PSUs) that, if earned, will be sett...
Neutral
PRNewsWire
6 days ago
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Cytokinetics, Inc. (NASDAQ: CYTK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Neutral
GlobeNewsWire
6 days ago
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 423
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today